Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan

for the Liver Cancer Study Group of Japan

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background: Beginning in 1967, the Liver Cancer Study Group of Japan (LCSGJ) started a nationwide prospective registry of all patients with hepatocellular carcinoma (HCC) diagnosed at more than 700 institutions. To determine the effectiveness of surveillance and treatment methods longitudinally, we analyzed improvements over time in overall survival (OS) of 173,378 patients with HCC prospectively entered into the LCSGJ registry between 1978 and 2005. Methods: All patients from more than 700 institutions throughout Japan with HCC were entered into the LCSGJ registry. Patients were grouped by years of diagnosis, with OS and 5-year OS rates being calculated. We also assessed OS and 5-year OS rates in patients who underwent resection, local ablation, transarterial chemoembolization (TACE), and hepatic arterial infusion chemotherapy (HAIC) and in those with baseline serum alpha-fetoprotein (AFP) levels ≥400 ng/ml. Results: The 5- and 10-year OS rates in the cohort of 173,378 patients were 37.9% and 16.5%, respectively. However, over time, the mean maximum tumor size decreased significantly, whereas 5-year OS rates and median survival time increased significantly. Similar findings were observed separately in patients who underwent resection, local ablation, TACE, and HAIC, as well as in patients with AFP levels ≥400 ng/ml. Conclusion: The establishment of a nationwide HCC surveillance program in Japan has contributed to longer median OS and increased OS rates in patients diagnosed with this disease. These findings suggest that the establishment of a surveillance program in other countries with patients at risk for HCC may provide significant survival benefits.

Original languageEnglish
Pages (from-to)190-197
Number of pages8
JournalLiver Cancer
Volume5
Issue number3
DOIs
Publication statusPublished - 2016 Jul 1

Fingerprint

Survival Analysis
Hepatocellular Carcinoma
Japan
Survival Rate
Survival
Liver Neoplasms
Registries
alpha-Fetoproteins
Drug Therapy
Liver

Keywords

  • Hepatic arterial infusion chemotherapy
  • Hepatocellular carcinoma
  • Liver Cancer Study Group of Japan
  • Nationwide survey
  • Overall survival

ASJC Scopus subject areas

  • Hepatology
  • Oncology

Cite this

Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan. / for the Liver Cancer Study Group of Japan.

In: Liver Cancer, Vol. 5, No. 3, 01.07.2016, p. 190-197.

Research output: Contribution to journalArticle

for the Liver Cancer Study Group of Japan. / Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan. In: Liver Cancer. 2016 ; Vol. 5, No. 3. pp. 190-197.
@article{7c7fa3f5665446a4b4ad42f016c9834e,
title = "Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan",
abstract = "Background: Beginning in 1967, the Liver Cancer Study Group of Japan (LCSGJ) started a nationwide prospective registry of all patients with hepatocellular carcinoma (HCC) diagnosed at more than 700 institutions. To determine the effectiveness of surveillance and treatment methods longitudinally, we analyzed improvements over time in overall survival (OS) of 173,378 patients with HCC prospectively entered into the LCSGJ registry between 1978 and 2005. Methods: All patients from more than 700 institutions throughout Japan with HCC were entered into the LCSGJ registry. Patients were grouped by years of diagnosis, with OS and 5-year OS rates being calculated. We also assessed OS and 5-year OS rates in patients who underwent resection, local ablation, transarterial chemoembolization (TACE), and hepatic arterial infusion chemotherapy (HAIC) and in those with baseline serum alpha-fetoprotein (AFP) levels ≥400 ng/ml. Results: The 5- and 10-year OS rates in the cohort of 173,378 patients were 37.9{\%} and 16.5{\%}, respectively. However, over time, the mean maximum tumor size decreased significantly, whereas 5-year OS rates and median survival time increased significantly. Similar findings were observed separately in patients who underwent resection, local ablation, TACE, and HAIC, as well as in patients with AFP levels ≥400 ng/ml. Conclusion: The establishment of a nationwide HCC surveillance program in Japan has contributed to longer median OS and increased OS rates in patients diagnosed with this disease. These findings suggest that the establishment of a surveillance program in other countries with patients at risk for HCC may provide significant survival benefits.",
keywords = "Hepatic arterial infusion chemotherapy, Hepatocellular carcinoma, Liver Cancer Study Group of Japan, Nationwide survey, Overall survival",
author = "{for the Liver Cancer Study Group of Japan} and Masatoshi Kudo and Namiki Izumi and Michiie Sakamoto and Yutaka Matsuyama and Takafumi Ichida and Osamu Nakashima and Osamu Matsui and Yonson Ku and Norihiro Kokudo and Masatoshi Makuuchi",
year = "2016",
month = "7",
day = "1",
doi = "10.1159/000367775",
language = "English",
volume = "5",
pages = "190--197",
journal = "Liver Cancer",
issn = "2235-1795",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan

AU - for the Liver Cancer Study Group of Japan

AU - Kudo, Masatoshi

AU - Izumi, Namiki

AU - Sakamoto, Michiie

AU - Matsuyama, Yutaka

AU - Ichida, Takafumi

AU - Nakashima, Osamu

AU - Matsui, Osamu

AU - Ku, Yonson

AU - Kokudo, Norihiro

AU - Makuuchi, Masatoshi

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Background: Beginning in 1967, the Liver Cancer Study Group of Japan (LCSGJ) started a nationwide prospective registry of all patients with hepatocellular carcinoma (HCC) diagnosed at more than 700 institutions. To determine the effectiveness of surveillance and treatment methods longitudinally, we analyzed improvements over time in overall survival (OS) of 173,378 patients with HCC prospectively entered into the LCSGJ registry between 1978 and 2005. Methods: All patients from more than 700 institutions throughout Japan with HCC were entered into the LCSGJ registry. Patients were grouped by years of diagnosis, with OS and 5-year OS rates being calculated. We also assessed OS and 5-year OS rates in patients who underwent resection, local ablation, transarterial chemoembolization (TACE), and hepatic arterial infusion chemotherapy (HAIC) and in those with baseline serum alpha-fetoprotein (AFP) levels ≥400 ng/ml. Results: The 5- and 10-year OS rates in the cohort of 173,378 patients were 37.9% and 16.5%, respectively. However, over time, the mean maximum tumor size decreased significantly, whereas 5-year OS rates and median survival time increased significantly. Similar findings were observed separately in patients who underwent resection, local ablation, TACE, and HAIC, as well as in patients with AFP levels ≥400 ng/ml. Conclusion: The establishment of a nationwide HCC surveillance program in Japan has contributed to longer median OS and increased OS rates in patients diagnosed with this disease. These findings suggest that the establishment of a surveillance program in other countries with patients at risk for HCC may provide significant survival benefits.

AB - Background: Beginning in 1967, the Liver Cancer Study Group of Japan (LCSGJ) started a nationwide prospective registry of all patients with hepatocellular carcinoma (HCC) diagnosed at more than 700 institutions. To determine the effectiveness of surveillance and treatment methods longitudinally, we analyzed improvements over time in overall survival (OS) of 173,378 patients with HCC prospectively entered into the LCSGJ registry between 1978 and 2005. Methods: All patients from more than 700 institutions throughout Japan with HCC were entered into the LCSGJ registry. Patients were grouped by years of diagnosis, with OS and 5-year OS rates being calculated. We also assessed OS and 5-year OS rates in patients who underwent resection, local ablation, transarterial chemoembolization (TACE), and hepatic arterial infusion chemotherapy (HAIC) and in those with baseline serum alpha-fetoprotein (AFP) levels ≥400 ng/ml. Results: The 5- and 10-year OS rates in the cohort of 173,378 patients were 37.9% and 16.5%, respectively. However, over time, the mean maximum tumor size decreased significantly, whereas 5-year OS rates and median survival time increased significantly. Similar findings were observed separately in patients who underwent resection, local ablation, TACE, and HAIC, as well as in patients with AFP levels ≥400 ng/ml. Conclusion: The establishment of a nationwide HCC surveillance program in Japan has contributed to longer median OS and increased OS rates in patients diagnosed with this disease. These findings suggest that the establishment of a surveillance program in other countries with patients at risk for HCC may provide significant survival benefits.

KW - Hepatic arterial infusion chemotherapy

KW - Hepatocellular carcinoma

KW - Liver Cancer Study Group of Japan

KW - Nationwide survey

KW - Overall survival

UR - http://www.scopus.com/inward/record.url?scp=85012839050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012839050&partnerID=8YFLogxK

U2 - 10.1159/000367775

DO - 10.1159/000367775

M3 - Article

AN - SCOPUS:85012839050

VL - 5

SP - 190

EP - 197

JO - Liver Cancer

JF - Liver Cancer

SN - 2235-1795

IS - 3

ER -